Literature DB >> 24781014

Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.

R Pippa1, A Dominguez1, D J Christensen2, I Moreno-Miralles1, M J Blanco-Prieto3, M P Vitek2, M D Odero4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24781014     DOI： 10.1038/leu.2014.141

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.

Authors:  Dale J Christensen; Nobutaka Ohkubo; Jessica Oddo; Michael J Van Kanegan; Jessica Neil; Fengqiao Li; Carol A Colton; Michael P Vitek
Journal:  J Immunol       Date:  2011-02-15       Impact factor: 5.422

2.  Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.

Authors:  Lisette Arnaud; She Chen; Fei Liu; Bin Li; Sabiha Khatoon; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2011-07-28       Impact factor: 4.124

Review 3.  Protein phosphatase 2A: a target for anticancer therapy.

Authors:  Danilo Perrotti; Paolo Neviani
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

4.  Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor.

Authors:  S Saito; M Miyaji-Yamaguchi; T Shimoyama; K Nagata
Journal:  Biochem Biophys Res Commun       Date:  1999-06-07       Impact factor: 3.575

5.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

7.  Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease.

Authors:  Guang Yu; Tonghai Yan; Ye Feng; Xinghua Liu; Yiyuan Xia; Hongbin Luo; Jian-Zhi Wang; Xiaochuan Wang
Journal:  Neurobiol Aging       Date:  2013-01-29       Impact factor: 4.673

8.  Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Authors:  Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Steve Roof; Jason G Harb; Greg Ferenchak; Ann-Kathrin Eisfeld; James R Van Brocklyn; Roger Briesewitz; Sahar A Saddoughi; Kyosuke Nagata; Robert Bittman; Michael A Caligiuri; Omar Abdel-Wahab; Ross Levine; Ralph B Arlinghaus; Alfonso Quintas-Cardama; John M Goldman; Jane Apperley; Alistair Reid; Dragana Milojkovic; Mark T Ziolo; Guido Marcucci; Besim Ogretmen; Paolo Neviani; Danilo Perrotti
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

9.  Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Authors:  Christopher J Walker; Joshua J Oaks; Ramasamy Santhanam; Paolo Neviani; Jason G Harb; Gregory Ferenchak; Justin J Ellis; Yosef Landesman; Ann-Kathrin Eisfeld; Nash Y Gabrail; Carrie L Smith; Michael A Caligiuri; Peter Hokland; Denis Claude Roy; Alistair Reid; Dragana Milojkovic; John M Goldman; Jane Apperley; Ramiro Garzon; Guido Marcucci; Sharon Shacham; Michael G Kauffman; Danilo Perrotti
Journal:  Blood       Date:  2013-08-22       Impact factor: 22.113

10.  Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.

Authors:  Sahar A Saddoughi; Salih Gencer; Yuri K Peterson; Katherine E Ward; Archana Mukhopadhyay; Joshua Oaks; Jacek Bielawski; Zdzislaw M Szulc; Raquela J Thomas; Shanmugam P Selvam; Can E Senkal; Elizabeth Garrett-Mayer; Ryan M De Palma; Dzmitry Fedarovich; Angen Liu; Amyn A Habib; Robert V Stahelin; Danilo Perrotti; Besim Ogretmen
Journal:  EMBO Mol Med       Date:  2012-11-25       Impact factor: 12.137
View more
  30 in total

1.  CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.

Authors:  Eva Barragán; María Carmen Chillón; Remedios Castelló-Cros; Nerea Marcotegui; María Isabel Prieto; Montserrat Hoyos; Raffaella Pippa; Marta Llop; Amaia Etxabe; José Cervera; Gabriela Rodríguez; Ismael Buño; José Rifón; Jorge Sierra; Marcos González; María J Calasanz; Miguel A Sanz; María D Odero
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

2.  PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.

Authors:  Xiaorong Zhou; Barrett L Updegraff; Yabin Guo; Michael Peyton; Luc Girard; Jill E Larsen; Xian-Jin Xie; Yunyun Zhou; Tae Hyun Hwang; Yang Xie; Jaime Rodriguez-Canales; Pamela Villalobos; Carmen Behrens; Ignacio I Wistuba; John D Minna; Kathryn A O'Donnell
Journal:  Cancer Res       Date:  2016-11-07       Impact factor: 12.701

3.  Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.

Authors:  M-H Hung; Y-L Chen; P-Y Chu; C-T Shih; H-C Yu; W-T Tai; C-W Shiau; K-F Chen
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

4.  SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses.

Authors:  Shaolong Zhang; Jingping Zhou; Pengzhao Shang; Guomeng Zhao; Anlei Wang; Jinlei Mao; Yuhang Tao; Ziyi Chen; Xuehao Wang; Changying Guo
Journal:  Exp Mol Med       Date:  2022-10-12       Impact factor: 12.153

Review 5.  Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.

Authors:  Godfrey Grech; Shawn Baldacchino; Christian Saliba; Maria Pia Grixti; Robert Gauci; Vanessa Petroni; Anthony G Fenech; Christian Scerri
Journal:  Tumour Biol       Date:  2016-07-21

Review 6.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.

Authors:  Caroline C Farrington; Eric Yuan; Sahar Mazhar; Sudeh Izadmehr; Lauren Hurst; Brittany L Allen-Petersen; Mahnaz Janghorban; Eric Chung; Grace Wolczanski; Matthew Galsky; Rosalie Sears; Jaya Sangodkar; Goutham Narla
Journal:  J Biol Chem       Date:  2019-12-10       Impact factor: 5.157

Review 8.  The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Authors:  Sathya Narayanan Patmanathan; Lee Fah Yap; Paul G Murray; Ian C Paterson
Journal:  J Cell Mol Med       Date:  2015-07-14       Impact factor: 5.310

9.  Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.

Authors:  Hao Liu; Yixue Gu; Hongsheng Wang; Jiang Yin; Guopei Zheng; Zhijie Zhang; Minyin Lu; Chenkun Wang; Zhimin He
Journal:  Oncotarget       Date:  2015-06-20

10.  Targeting of SET/I2PP2A oncoprotein inhibits Gli1 transcription revealing a new modulator of Hedgehog signaling.

Authors:  Iliana Serifi; Simoni Besta; Zoe Karetsou; Panagiota Giardoglou; Dimitris Beis; Pawel Niewiadomski; Thomais Papamarcaki
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.